Thiogenesis Therapeutics, Corp.
TTI.V
TSX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 38.64% | 7.13% | 54.59% | 16.20% | 28.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 147.99% | 58.00% | -39.81% | -39.15% | -18.19% |
| Operating Income | -147.99% | -58.00% | 39.81% | 39.15% | 18.19% |
| Income Before Tax | -188.42% | -86.53% | 47.12% | 38.74% | 26.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -188.42% | -86.53% | 47.12% | 38.74% | 26.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -188.42% | -86.53% | 47.12% | 38.74% | 26.53% |
| EBIT | -147.99% | -58.00% | 39.81% | 39.15% | 18.19% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -181.90% | -81.36% | 53.81% | 47.52% | 37.13% |
| Normalized Basic EPS | -184.62% | -81.08% | 53.78% | 47.62% | 37.50% |
| EPS Diluted | -181.90% | -81.36% | 53.81% | 47.52% | 37.13% |
| Normalized Diluted EPS | -184.62% | -81.08% | 53.78% | 47.62% | 37.50% |
| Average Basic Shares Outstanding | 1.78% | 2.99% | 14.59% | 17.08% | 17.07% |
| Average Diluted Shares Outstanding | 1.78% | 2.99% | 14.59% | 17.08% | 17.07% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |